



NATIONAL LUNG CANCER ROUNDTABLE

BIOMARKER TESTING IN LUNG CANCER: A CONSENSUS STATEMENT

M. Patricia Rivera, MD

University of North Carolina at Chapel Hill

Biomarker Testing in Lung Cancer: A Consensus Statement

- **National Summit on Optimizing Lung Cancer Biomarkers in Practice**
 - September 2020
 - Biomarker Steering Committee Strategic Plan
 - Strategies to be adopted by NLCRT member organizations for increasing awareness of comprehensive biomarker testing in appropriate patients
 - Deliver the most effective treatments to lung cancer patients
 - ***Biomarker consensus statement one of the proposed priorities***

Biomarker Testing in Lung Cancer: A Consensus Statement

- ***Why is a consensus statement needed?***
 - Guidelines are difficult to follow, find, and implement
 - Promoted by individual societies to their own membership
- ***Goal:***
 - Harmonize existing professional society guidelines (CAP/AMP/IASLC and NCCN), complimented by ASCO treatment guidelines.
 - Identify areas of concordance of dissimilarity
 - Collate and synthesize the most current existing information
 - Develop a multi-specialty/society statement on comprehensive biomarker testing for NSCLC
 - Endorse best practice
 - Enhance communication among clinicians
 - Promoted to NLCRT members, amplified by NLCRT members to their constituents, available to all

Biomarker Testing in Lung Cancer: A Consensus Statement

Committee Members

- **Multidisciplinary – across all stakeholder groups and institutions (academic and community)**

- M. Patricia Rivera, MD, University of North Carolina at Chapel Hill
- Gerard Silvestri, MD, MS, Medical University of South Carolina
- George Eapen, MD, MD Anderson Cancer Center
- Michael Nead, MD, PhD, University of Rochester Medical Center
- Nicholas Pastis, MD, Ohio State University
- Catherine Sears, MD, Indiana University
- Jasleen Pannu, MBBS, Ohio State University
- Farhood Farjah, MD, MPH, University of Washington
- Bruce Johnson, MD, Dana-Farber Cancer Institute
- Raymond Osarogiagbon, MBBS, Baptist Cancer Center
- Shetal Patel, MD, PhD, University of North Carolina at Chapel Hill
- Omar Atiq, MD, University of Arkansas for Medical Sciences
- Karen Kelly, MD, University of California at Davis
- Edward Kim, MD, MBA, City of Hope Orange County
- Ignacio Wistuba, MD, MD Anderson Cancer Center
- Lynette Sholl, MD, Dana-Farber Cancer Institute
- Bart Singer, MD, University of North Carolina at Chapel Hill
- Robert Smith, PhD, American Cancer Society

Biomarker Testing in Lung Cancer: A Consensus Statement

- **Methods:**
 - Committee members identify common and dissimilar elements of the leading guidelines
 - Patients who should undergo molecular biomarker testing
 - Patients who should undergo diagnostic biomarker testing (PD-L1)
 - What specimens to test
 - How to test, next generation sequencing (other aspects of the testing and reporting) process
- Delphi method
 - Construct and administer questionnaire with the best and most current information
 - Analyze responses and re administer questionnaire
 - Verify degree of convergence
- Develop a consensus statement
- Promote/disseminate